Regeneron Pharmaceuticals, Inc. (REGN) Stock Forecast & Predictions

Regeneron Pharmaceuticals, Inc. REGN: $490.43

777 Old Saw Mill River Rd, Tarrytown, New York, US. | Sector: Manufacturing | Exchange: NASDAQ/NGS (GLOBAL SELECT MARKET) | Web: https://www.regeneron.com/

  • Market Cap$53.32B
  • Change (52 Weeks)-9.25%
  • Low (52 Weeks)$441
  • Regeneron Pharmaceuticals, Inc. (REGN) Forecast Based on Technical Analysis


    Neutral
    Based on 16 Technical Indicators where 6.25% are on Buy, 43.75% on Sell, and 50.00% Neutral.

    According to the market data, Regeneron Pharmaceuticals, Inc. (REGN) stock price is $490.43 and the 52 weeks low is $441, which means the Regeneron Pharmaceuticals, Inc. stock price is down -9.25% in the last 12 months.

    Regeneron Pharmaceuticals, Inc. (REGN) Stock Price is not Trending currently as per the Weekly Chart, which means the price may range between specific high and low levels for the next few months, unless some significant changes take place in the market performance or news.

    Technical Indicators are algorithms that are used mostly by Technical traders to predict the price action of a stock.

    Based on our analysis of 16 technical indicators, 6.25% are indicating that REGN Stock price might rise further, 43.75% indicating that REGN Stock price might fall, and 50.00% are in a neutral position.

    Based on these technical algorithms, overall REGN stock price has a Neutral Signal, which means the stock price has the potential to move either up or down, depending on the nature of consolidating market phase, since majority of indicators are providing a neutral signal.

    Regeneron Pharmaceuticals, Inc. (REGN) Stock Forecast By Analysts


    Strong Buy
    Analysts Recommendations for Regeneron Pharmaceuticals, Inc. (REGN) is based on 32 Institutional Analyst Ratings where 37.50% are on Strong Buy, 34.38% on Moderate Buy, 28.13% remains on Hold, 0.00% are on Moderate Sell and 0.00% are on Strong Sell.

    Out of 32 Institutional Analysts, majority recommended REGN stock as Strong Buy. Since most investors and traders follow analyst ratings closely, this can be a potentially driving factor for the future stock price of Regeneron Pharmaceuticals, Inc..

    Regeneron Pharmaceuticals, Inc. (REGN) Stock Price Prediction By Analysts


    HighLowAverage
    $833.70$481.77$656.23
    $656.2333.81% Upside
    Updated: 2021-04-22 00:00:00

    The Average Price target for REGN set by the institutional analysts is $656.23 where High Estimate is $833.70, Median $652.29 and Low $481.77.

    The average price target for REGN by Institutional Analysts is $656.23, which is 33.81% Upside from the current price. So according to the Institutional Analysts, REGN Stock might be a bit undervalued at this stage and there’s potential for upside.

    However, although Institutional Analysts set their price targets after extensive research, they’re not always correct. After all, the market is mostly driven by investors speculation and emotion than just concrete numbers.

    Regeneron Pharmaceuticals, Inc. (REGN) Stock Forecast Based on News Sentiment


    Bullish
    Based on 17 articles published Last Week, where 100.00% are Bullish and 0.00% are Bearish.

    According to the news articles published last week, most journalists and bloggers talked positively about REGN, it shows that Regeneron Pharmaceuticals, Inc. had a 100.00% positive news coverage.

    Positive news coverage usually affects short-term price of a stock, so this positive coverage provides an indication that REGN stock price may surge in the next few weeks.

    Regeneron Pharmaceuticals, Inc. (REGN) Stock Forecasts By Institutional Analysts


    Analyst
    Recommendation
    Action
    Morgan StanleyEqual-WeightMaintained
    SVB LeerinkOutperformMaintained
    Credit SuisseOutperformMaintained
    Cantor FitzgeraldOverweightMaintained
    SVB LeerinkOutperformMaintained
    Morgan StanleyEqual-WeightMaintained
    Credit SuisseOutperformMaintained
    Cowen & Co.OutperformMaintained
    BMO CapitalOutperformUpgraded
    Morgan StanleyEqual-WeightMaintained
    CitigroupBuyMaintained
    BenchmarkBuyUpgraded
    Morgan StanleyEqual-WeightMaintained
    Credit SuisseOutperformMaintained
    Morgan StanleyEqual-WeightMaintained
    SVB LeerinkOutperformMaintained
    Credit SuisseOutperformMaintained
    BMO CapitalMarket PerformMaintained
    Morgan StanleyEqual-WeightMaintained
    SVB LeerinkOutperformMaintained
    Cantor FitzgeraldOverweightUpgraded
    BenchmarkHoldDowngraded
    Credit SuisseOutperformMaintained
    Morgan StanleyEqual-WeightMaintained
    CitigroupNeutralMaintained
    BMO CapitalMarket PerformMaintained
    Credit SuisseOutperformMaintained
    Morgan StanleyEqual-WeightMaintained
    SunTrust Robinson HumphreyBuyUpgraded
    Canaccord GenuityBuyMaintained
    OppenheimerOutperformMaintained
    Credit SuisseOutperformMaintained
    JefferiesBuyMaintained
    SVB LeerinkOutperformReiterated
    CFRAHoldMaintained
    Wells FargoOverweightUpgraded
    SVB LeerinkOutperformMaintained
    Morgan StanleyEqual-WeightMaintained
    Credit SuisseOutperformMaintained
    BMO CapitalMarket PerformMaintained
    BairdNeutralMaintained
    CitigroupNeutralDowngraded
    Canaccord GenuityBuyMaintained
    BenchmarkBuyUpgraded
    Morgan StanleyEqual-WeightMaintained
    JP MorganNeutralMaintained
    BenchmarkHoldInitiated
    SVB LeerinkOutperformMaintained
    Wells FargoEqual-WeightMaintained
    Argus ResearchBuyMaintained
    OppenheimerOutperformMaintained
    CFRAHoldDowngraded
    Credit SuisseOutperformMaintained
    Canaccord GenuityBuyUpgraded
    BairdNeutralDowngraded
    JefferiesBuyUpgraded
    Evercore ISI GroupOutperformUpgraded
    Argus ResearchBuyUpgraded
    Morgan StanleyEqual-WeightMaintained
    Morgan StanleyEqual-WeightMaintained
    Raymond JamesMarket PerformInitiated
    Evercore ISI GroupIn-LineDowngraded
    Credit SuisseOutperformUpgraded
    SunTrust Robinson HumphreyHoldInitiated
    CitigroupBuyUpgraded
    Morgan StanleyEqual-WeightMaintained
    Credit SuisseNeutralMaintained
    BMO CapitalMarket PerformMaintained
    Canaccord GenuityHoldMaintained
    GuggenheimBuyUpgraded
    BairdOutperformUpgraded
    ArgusHoldDowngraded
    CitigroupNeutralMaintained
    Credit SuisseNeutralInitiated
    Cantor FitzgeraldNeutralMaintained
    UBSBuyMaintained
    Morgan StanleyEqual-WeightMaintained
    BMO CapitalMarket PerformMaintained
    GuggenheimNeutralDowngraded
    GuggenheimBuyUpgraded
    Goldman SachsBuyUpgraded
    Morgan StanleyEqual-WeightMaintained
    Canaccord GenuityHoldMaintained
    Cantor FitzgeraldNeutralInitiated
    BarclaysUnderweightMaintained
    Morgan StanleyEqual-WeightMaintained
    Canaccord GenuityHoldMaintained
    BairdNeutralDowngraded
    ArgusBuyMaintained
    Morgan StanleyEqual-WeightMaintained
    OppenheimerOutperformUpgraded
    Morgan StanleyEqual-WeightMaintained
    BMO CapitalMarket PerformMaintained
    GuggenheimNeutralDowngraded
    Raymond JamesMarket PerformDowngraded
    Canaccord GenuityHoldDowngraded
    Morgan StanleyEqual-WeightMaintained
    Leerink SwannOutperformMaintained
    BTIG ResearchNeutralDowngraded
    BMO CapitalMarket PerformMaintained
    BairdOutperformUpgraded
    JP MorganNeutralMaintained
    Deutsche BankHoldInitiated
    CitigroupNeutralDowngraded
    BTIG ResearchBuyMaintained
    Morgan StanleyEqual-WeightMaintained
    BMO CapitalMarket PerformMaintained
    BairdNeutralUpgraded
    BarclaysUnderweightDowngraded
    Morgan StanleyEqual-WeightMaintained
    UBSBuyMaintained
    RBC CapitalSector PerformInitiated
    Evercore ISI GroupOutperformInitiated
    BairdUnderperformDowngraded
    Morgan StanleyEqual-WeightMaintained
    BernsteinMarket PerformDowngraded
    Canaccord GenuityBuyUpgraded
    UBSBuyInitiated
    PiperJaffrayOverweightUpgraded
    BMO CapitalMarket PerformInitiated
    BTIG ResearchBuyUpgraded
    Chardan CapitalNeutralUpgraded
    BairdNeutralDowngraded
    BernsteinOutperformInitiated
    Wells FargoMarket PerformDowngraded
    Roth CapitalBuyMaintained
    Leerink SwannOutperformMaintained
    Chardan CapitalSellDowngraded
    Gabelli & Co.BuyInitiated
    SunTrust Robinson HumphreyNeutralInitiated
    CitigroupBuyInitiated
    Chardan CapitalNeutralUpgraded
    UBSBuyMaintained
    Morgan StanleyEqual-WeightMaintained
    JP MorganNeutralMaintained
    Brean CapitalBuyMaintained
    BarclaysEqual-WeightMaintained
    Leerink SwannOutperformInitiated
    Canaccord GenuityHoldDowngraded
    Chardan CapitalSellDowngraded
    Credit SuisseNeutralInitiated
    Roth CapitalBuyUpgraded
    BTIG ResearchNeutralInitiated
    Wells FargoOutperformInitiated
    Morgan StanleyEqual-WeightDowngraded
    UBSBuyUpgraded
    Chardan CapitalNeutralDowngraded
    BarclaysEqual-WeightMaintained
    Morgan StanleyOverweightMaintained
    Brean CapitalBuyMaintained
    JefferiesHoldMaintained
    RBC CapitalOutperformMaintained
    Deutsche BankBuyMaintained
    UBSSellDowngraded
    RBC CapitalOutperformMaintained
    BairdOutperformMaintained
    CitigroupBuyMaintained
    Leerink SwannOutperformMaintained
    Chardan CapitalBuyInitiated
    BernsteinOutperformInitiated
    PiperJaffrayNeutralDowngraded
    CitigroupBuyMaintained
    BarclaysEqual-weightInitiated
    Morgan StanleyOverweightUpgraded
    Bank of AmericaBuyMaintained
    Brean CapitalBuyMaintained
    ArgusBuyMaintained
    GuggenheimBuyInitiated
    Credit SuisseOutperformMaintained
    Brean CapitalBuyMaintained
    Deutsche BankBuyMaintained
    Argus CapitalBuyInitiated
    UBSNeutralMaintained
    Canaccord GenuityBuyInitiated
    Roth CapitalBuyMaintained
    Morgan StanleyEqual-WeightInitiated
    CitigroupBuyUpgraded
    OppenheimerMarket PerformDowngraded
    Deutsche BankBuyMaintained
    CitigroupNeutralMaintained
    BMO CapitalMarket PerformDowngraded
    PiperJaffrayOverweightInitiated
    BMO CapitalOutperformMaintained
    PiperJaffrayOverweightMaintained
    Leerink SwannOutperformMaintained
    Deutsche BankBuyMaintained
    Bank of AmericaBuyMaintained
    PiperJaffrayOverweightMaintained
    OppenheimerOutperformMaintained
    Goldman SachsBuyMaintained
    RBC CapitalOutperformMaintained
    LazardBuyMaintained
    OppenheimerOutperformInitiated
    PiperJaffrayOverweightMaintained
    LazardBuyUpgraded
    PiperJaffrayOverweightUpgraded
    Brean CapitalBuyUpgraded
    Goldman SachsBuyMaintained
    Bank of AmericaBuyMaintained
    Goldman SachsBuyMaintained
    JMP SecuritiesMarket PerformInitiated
    BarclaysOverweightInitiated
    Brean CapitalHoldDowngraded
    JefferiesHoldDowngraded
    Credit SuisseOutperformInitiated
    Deutsche BankBuyMaintained
    JefferiesBuyMaintained
    Goldman SachsBuyMaintained
    Deutsche BankBuyMaintained
    CitigroupNeutralMaintained
    PiperJaffrayNeutralMaintained
    Bank of AmericaBuyMaintained
    Goldman SachsBuyMaintained
    Bank of AmericaBuyMaintained
    PiperJaffrayNeutralMaintained
    BMO CapitalOutperformUpgraded
    Bank ofericaBuyMaintained
    JefferiesBuyMaintained
    Goldman SachsBuyMaintained
    Bank ofericaBuyMaintained
    JefferiesBuyMaintained
    PiperJaffrayNeutralMaintained
    Brean CapitalBuyMaintained
    Bank ofericaBuyMaintained
    Bank ofericaBuyMaintained
    Bank ofericaBuyMaintained
    PiperJaffrayNeutralMaintained

    Regeneron Pharmaceuticals, Inc. (REGN) Stock Earning Per Share (EPS) Forecast / Estimate


    $14.641
    The average consensus EPS for REGN is $14.641 with a high estimate of $23.499 and Low of $7.272 for the period 2021-06-30 and based on 22 Institutional Analysts.

    Last Quarter


    Actual
    Estimate
    Date
    $8.36$7.27805699999999962020-09-30


    The latest average Earning Per Share Estimate for Regeneron Pharmaceuticals, Inc. is $14.64, which is higher than REGN's last EPS, $8.36. This means that Analysts are expecting Regeneron Pharmaceuticals, Inc. to report higher earnings. This can drive share prices higher since the investors have positive sentiment about market performance of Regeneron Pharmaceuticals, Inc..

    Earning Per Share (EPS) History


    Actual
    Estimate
    Date
    $8.36$7.27805699999999962020-09-30
    $7.16$6.1028642020-06-30
    $6.6$6.2543852020-03-31
    $7.5$7.06108262019-12-31
    $6.67$6.48918900000000052019-09-30
    $6.02$5.5152012000000012019-06-30
    $4.45$5.58296999999999952019-03-31
    $6.84$5.71050060000000052018-12-31
    $5.87$5.2357112018-09-30
    $5.45$4.7900627999999992018-06-30
    $4.67$4.43978462018-03-31
    $5.23$4.61762162017-12-31
    $3.99$3.92611262017-09-30
    $4.17$3.23092142017-06-30
    $2.92$3.12251582017-03-31
    $3.04$3.08810100000000042016-12-31
    $3.13$2.76081362016-09-30
    $2.82$2.70239822016-06-30
    $2.57$2.63272200000000022016-03-31
    $2.83$3.42575162015-12-31
    $3.47$3.259412015-09-30
    $2.89$2.826932015-06-30
    $2.88$2.73615000000000032015-03-31
    $2.79$2.87219762014-12-31
    $2.52$2.625482014-09-30
    $2.47$2.34092014-06-30
    $2.26$2.2442014-03-31
    $0.86$1.00219082013-12-31
    $1.25$0.92247782013-09-30
    $0.79$0.89477462013-06-30
    $0.9$0.99769262013-03-31
    $1.22$1.12131659999999992012-12-31
    $1.72$0.96392012-09-30
    $0.7$0.27175862012-06-30
    $0.16$-0.23462012-03-31
    $-0.54$-0.61272419999999992011-12-31
    $-0.68$-0.77316000000000012011-09-30
    $-0.69$-0.416496600000000052011-06-30
    $-0.49$-0.365162011-03-31
    $-0.17$-0.328442010-12-31

    What is Analyst Ratings & Price Targets?

    The analysts provide Buy, Sell or Hold ratings after extensive research of a companies financial reports, listening to conference calls and some of them even get in contact with upper management of the company to get an overall picture of operation.

    Although institutional Analyst’s are not always correct, their ratings are followed by millions of traders around the world and they can heavily influence trading activities for a company.

    As a retail investor, going through analyst ratings will instantly provide you an idea if the stock is worth buying. Top Analysts also provide their price targets. It’s a prediction of where the stock price might go based on their analysis.

    The best way to analyze price targets is to combined average price targets of major analysts. If the average price target is much higher than the current price of the stock, then the probability of a stock going up is also high.

    What is Technical Analysis?

    Technical Analysis refers to analyzing a stock's price over a period of time. In the financial market, past price patterns are one of the strongest indicators of an asset's future performance.

    In easier terms, millions of traders use Live Charts to watch the stock prices, it is actually a single source of truth for most traders. When a stock's price reaches a significant price level/pattern in the chart, millions of traders take buy/sell positions from those levels.

    As a regular investor, one of the easiest ways to check technical analysis of a stock is through Technical Indicators. Technical Indicators are programmed algorithms that monitor price changes in the Charts and indicate Buy/Sell based on market conditions.

    Some Technical Indicators can be very powerful (e.g SMA) and some can be pretty useless. Stock research tools like iTradely heavily simplify the technical analysis process for the investors by showing Buy/Sell/Neutral ratings combined from 17 powerful technical indicators, all in one page.

    What is Earnings Per Share (EPS) and Why is it Important?

    EPS, or Earning Per Share, can tell a lot about a stock’s performance. It’s calculated by dividing a company’s profit by the number of outstanding shares of its common stocks.

    In layman’s term, earnings is an indicator of a company’s profitability. Higher the earnings, the more profitable a company is.
    Some traders pick stocks solely based on EPS or earnings Analysis, it is a very powerful indicator of a stock’s price.

    Before you buy a stock, check the company’s earnings History and Surprises. A Surprise happens when a company reports a much higher or lower actual earnings/EPS than the forecasted earnings/EPS.

    If a company reports higher EPS surprises consistently, analysts keep raising their estimates, traders become more confident in the company, driving the share price higher.

    What is Stock Sentiment?

    Stock Sentiment refers to how people speculating about the stock or what kind of trading position investors are often taking.

    There are different kinds of sentiments you can find online for a company, this includes Investor Sentiment (Percentage of investors buying or selling), News Sentiment (Is the company getting positive or negative impressions from the Press?), Social Sentiment (The overall trends about the company in social media, is it negative or positive?).